^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Neuroendocrine Tumor

No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
everolimus
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
sunitinib
Sensitive
:
A1
VHL mutation
Neuroendocrine Tumor
belzutifan
Sensitive
:
A1
No biomarker
Neuroendocrine Tumor
EP
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
octreotide
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
temozolomide
Sensitive
:
A2
SSTR positive
Neuroendocrine Tumor
lanreotide prolonged-release subcutaneous
Sensitive
:
A2
SSTR positive
Neuroendocrine Tumor
octreotide
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
FOLFOX
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
carboplatin + etoposide IV
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
temozolomide + capecitabine
Sensitive
:
A2
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
oxaliplatin
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
dacarbazine
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
cisplatin + etoposide IV
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
5-fluorouracil
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
capecitabine
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
FOLFIRINOX
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
carboplatin + irinotecan
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
cisplatin + irinotecan
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
FOLFIRI
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
CAPOX
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
5-fluorouracil + streptozocin
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
doxorubicin hydrochloride + streptozocin
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
streptozocin
Sensitive
:
A2
TMB-H
Neuroendocrine Tumor
pembrolizumab
Sensitive
:
A2
No biomarker
Neuroendocrine Tumor
FAS
Sensitive
:
A2